SciSparc Ltd. (SPRC), a pharmaceutical company specializing in cannabinoid-based treatments, has received FDA approval to proceed with a Phase IIb clinical trial for its Tourette Syndrome (TS) medication, SCI-110. The trial will evaluate the drug’s efficacy, safety, and tolerability in adults, building upon promising results from earlier studies.
Clearmind Medicine has filed a patent for a new combination therapy for addiction, involving Ibogaine and Palmitoylethanolamide (PEA). The therapy, developed in collaboration with SciSparc, aims to improve the safety and efficacy of Ibogaine-based treatments for opioid, cocaine, and other substance use disorders.
Lumentum Holdings Inc. (LITE) shares surged in pre-market trading after reporting better-than-expected fourth-quarter results and issuing strong first-quarter revenue guidance. Other notable pre-market movers include SciSparc Ltd. (SPRC), VS MEDIA Holdings Limited (VSME), and Altamira Therapeutics Ltd. (CYTO), all experiencing significant gains. On the other hand, Turnstone Biologics Corp. (TSBX) and Titan Machinery Inc. (TITN) saw declines after reporting disappointing financial results.
